These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

637 related items for PubMed ID: 3925239

  • 1. Characterization of cutaneous vascular permeability induced by platelet-activating factor in guinea pigs and rats and its inhibition by a platelet-activating factor receptor antagonist.
    Hwang SB, Li CL, Lam MH, Shen TY.
    Lab Invest; 1985 Jun; 52(6):617-30. PubMed ID: 3925239
    [Abstract] [Full Text] [Related]

  • 2. The isolation and characterization of kadsurenone from haifenteng (Piper futokadsura) as an orally active specific receptor antagonist of platelet-activating factor.
    Shen TY, Hwang SB, Chang MN, Doebber TW, Lam MH, Wu MS, Wang X.
    Int J Tissue React; 1985 Jun; 7(5):339-43. PubMed ID: 2997065
    [Abstract] [Full Text] [Related]

  • 3. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).
    Merlos M, Giral M, Balsa D, Ferrando R, Queralt M, Puigdemont A, García-Rafanell J, Forn J.
    J Pharmacol Exp Ther; 1997 Jan; 280(1):114-21. PubMed ID: 8996188
    [Abstract] [Full Text] [Related]

  • 4. Anti-anaphylactic activity of the novel selective histamine H1 receptor antagonist mizolastine in the rodent.
    Levrier J, Duval D, Prouteau M, Voltz C, Berry CN, Lloyd KG, Scatton B.
    Arzneimittelforschung; 1995 May; 45(5):559-68. PubMed ID: 7541995
    [Abstract] [Full Text] [Related]

  • 5. Pharmacology of a potent platelet-activating factor antagonist: Ro 24-4736.
    Crowley HJ, Yaremko B, Selig WM, Janero DR, Burghardt C, Welton AF, O'Donnell M.
    J Pharmacol Exp Ther; 1991 Oct; 259(1):78-85. PubMed ID: 1656030
    [Abstract] [Full Text] [Related]

  • 6. Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor.
    Heuer HO, Casals-Stenzel J, Muacevic G, Weber KH.
    J Pharmacol Exp Ther; 1990 Dec; 255(3):962-8. PubMed ID: 2262914
    [Abstract] [Full Text] [Related]

  • 7. Characterization of a platelet-activating factor receptor antagonist isolated from haifenteng (Piper futokadsura): specific inhibition of in vitro and in vivo platelet-activating factor-induced effects.
    Shen TY, Hwang SB, Chang MN, Doebber TW, Lam MH, Wu MS, Wang X, Han GQ, Li RZ.
    Proc Natl Acad Sci U S A; 1985 Feb; 82(3):672-6. PubMed ID: 2983307
    [Abstract] [Full Text] [Related]

  • 8. trans-2,5-Bis-(3,4,5-trimethoxyphenyl)tetrahydrofuran. An orally active specific and competitive receptor antagonist of platelet activating factor.
    Hwang SB, Lam MH, Biftu T, Beattie TR, Shen TY.
    J Biol Chem; 1985 Dec 15; 260(29):15639-45. PubMed ID: 2999126
    [Abstract] [Full Text] [Related]

  • 9. Effect of platelet-activating factor and its specific receptor antagonist on glomerular permeability to proteins in isolated perfused rat kidney.
    Perico N, Delaini F, Tagliaferri M, Abbate M, Cucchi M, Bertani T, Remuzzi G.
    Lab Invest; 1988 Feb 15; 58(2):163-71. PubMed ID: 3123798
    [Abstract] [Full Text] [Related]

  • 10. Bepotastine besilate, a highly selective histamine H(1) receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models.
    Kida T, Fujii A, Sakai O, Iemura M, Atsumi I, Wada T, Sakaki H.
    Exp Eye Res; 2010 Jul 15; 91(1):85-91. PubMed ID: 20412793
    [Abstract] [Full Text] [Related]

  • 11. Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor.
    Casals-Stenzel J, Muacevic G, Weber KH.
    J Pharmacol Exp Ther; 1987 Jun 15; 241(3):974-81. PubMed ID: 3598913
    [Abstract] [Full Text] [Related]

  • 12. Pharmacological profile of UK-74,505, a novel and selective PAF antagonist with potent and prolonged oral activity.
    Parry MJ, Alabaster VA, Cheeseman HE, Cooper K, deSouza RN, Keir RF.
    J Lipid Mediat Cell Signal; 1994 Sep 15; 10(3):251-68. PubMed ID: 7812676
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Biochemical and pharmacological characterization of L-659,989: an extremely potent, selective and competitive receptor antagonist of platelet-activating factor.
    Hwang SB, Lam MH, Alberts AW, Bugianesi RL, Chabala JC, Ponpipom MM.
    J Pharmacol Exp Ther; 1988 Aug 15; 246(2):534-41. PubMed ID: 2841449
    [Abstract] [Full Text] [Related]

  • 15. Antiallergic effect of epinastine (WAL 801 CL) on immediate hypersensitivity reactions: (II). Antagonistic effect of epinastine on chemical mediators, mainly antihistaminic and anti-PAF effects.
    Kamei C, Mio M, Kitazumi K, Tsujimoto S, Yoshida T, Adachi Y, Tasaka K.
    Immunopharmacol Immunotoxicol; 1992 Aug 15; 14(1-2):207-18. PubMed ID: 1350791
    [Abstract] [Full Text] [Related]

  • 16. Differences in platelet-activating factor receptor mediated Ca++ response between hamster and guinea pig alveolar macrophages.
    Chen J, Giri SN.
    J Pharmacol Exp Ther; 1997 Jun 15; 281(3):1047-58. PubMed ID: 9190835
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. MK 287: a potent, specific, and orally active receptor antagonist of platelet-activating factor.
    Hwang SB, Lam MH, Szalkowski DM, MacIntyre DE, Bach TJ, Luell S, Meuer R, Sahoo SP, Alberts AW, Chabala JC.
    J Lipid Mediat; 1993 Jun 15; 7(2):115-34. PubMed ID: 8400114
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.